138 related articles for article (PubMed ID: 36795284)
1. Mucinous adenocarcinoma of the prostatic urethra after brachytherapy.
Isharwal S; Gupta S; Ortiz N; Greene KL
Int Urol Nephrol; 2023 Jun; 55(6):1477-1479. PubMed ID: 36795284
[No Abstract] [Full Text] [Related]
2. Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series.
Zhao T; Chuang HW; Cornejo KM; Crotty RK; Dahl DM; Wszolek MF; Zlatev DV; Zietman AL; Wu CL
Hum Pathol; 2022 Oct; 128():101-109. PubMed ID: 35926810
[TBL] [Abstract][Full Text] [Related]
3. Secondary mucinous carcinoma of the prostate after low dose rate brachytherapy.
Murchison SC; Martens MB; Truong P; Alexander A
Can J Urol; 2018 Apr; 25(2):9284-9287. PubMed ID: 29680008
[TBL] [Abstract][Full Text] [Related]
4. Prostate mucinous adenocarcinoma with signet ring cell.
Gumus E; Yilmaz B; Miroglu C
Int J Urol; 2003 Apr; 10(4):239-41. PubMed ID: 12657107
[TBL] [Abstract][Full Text] [Related]
5. The dosimetry of prostate brachytherapy-induced urethral strictures.
Merrick GS; Butler WM; Tollenaar BG; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):461-8. PubMed ID: 11872293
[TBL] [Abstract][Full Text] [Related]
6. A surrogate urethra for real-time planning of high-dose-rate prostate brachytherapy.
Halperin H; Hilts M; Crook J; Batchelar D; Tisseverasinghe S; Tetreault-LaFlamme A; Bachand F
Brachytherapy; 2019; 18(5):675-682. PubMed ID: 31248822
[TBL] [Abstract][Full Text] [Related]
7. Mucinous adenocarcinoma of the prostate.
Chica G; Johnson DE; Ayala AG
J Urol; 1977 Jul; 118(1 Pt 1):124-5. PubMed ID: 195095
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the dose to the bulbomembranous urethra and stricture after high dose-rate brachytherapy for prostate cancer: Matched-pair analysis.
Sekiguchi A; Tsumura H; Kawakami S; Satoh T; Iwamura M; Ishiyama H
Int J Urol; 2019 Sep; 26(9):938-939. PubMed ID: 31256422
[No Abstract] [Full Text] [Related]
9. Acute urinary retention after I-125 prostate brachytherapy in relation to dose in different regions of the prostate.
Roeloffzen EM; Monninkhof EM; Battermann JJ; van Roermund JG; Moerland MA; van Vulpen M
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):76-84. PubMed ID: 20605364
[TBL] [Abstract][Full Text] [Related]
10. Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer.
Kaufman DS; Zietman AL; Dahl DM; Harisinghani MG; Wu CL
N Engl J Med; 2011 Feb; 364(7):667-75. PubMed ID: 21323545
[No Abstract] [Full Text] [Related]
11. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer.
Morton GC; Loblaw DA; Chung H; Tsang G; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Batchelar D; Danjoux C; Szumacher E
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1299-305. PubMed ID: 20708853
[TBL] [Abstract][Full Text] [Related]
12. Mucinous and secondary tumors of the prostate.
Osunkoya AO
Mod Pathol; 2018 Jan; 31(S1):S80-S95. PubMed ID: 29297488
[TBL] [Abstract][Full Text] [Related]
13. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
[TBL] [Abstract][Full Text] [Related]
15. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
[TBL] [Abstract][Full Text] [Related]
16. An open-source genetic algorithm for determining optimal seed distributions for low-dose-rate prostate brachytherapy.
McGeachy P; Madamesila J; Beauchamp A; Khan R
Brachytherapy; 2015; 14(5):692-702. PubMed ID: 26023047
[TBL] [Abstract][Full Text] [Related]
17. Rectal adenocarcinoma with rectoprostatic fistula following prostate brachytherapy.
Moss BF; Peracha AM
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30936326
[TBL] [Abstract][Full Text] [Related]
18. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.
Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828
[TBL] [Abstract][Full Text] [Related]
19. [Curative radiotherapy in stage C prostatic carcinoma. Experiences with radiotherapy-endocrine treatment].
Klosterhalfen H; Becker H; Köllermann MW; Altenähr E
Urologe A; 1983 Sep; 22 Suppl():360-6. PubMed ID: 6314624
[TBL] [Abstract][Full Text] [Related]
20. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.
Raleigh DR; Chang AJ; Tomlin B; Cunha JA; Braunstein SE; Shinohara K; Gottschalk AR; Roach M; Hsu IC
Brachytherapy; 2015; 14(6):795-800. PubMed ID: 26198421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
